Cephalon today announced that it has filed a lawsuit in U.S. District Court of Delaware against Watson for infringement of US6200604 (Expiry: Mar 26, 2019) and US6974590 (Expiry: Mar 26, 2019), which cover methods of use for the O.B listed product Fentora (Fentanyl buccal tablet).
Fentanyl (N-(1-(2-phenylethyl)-4-piperidinyl)-N-phenyl-propanamide) was approved by the USFDA in September 2006 for the management of breakthrough pain in patients with cancer who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain. One advantage of such tablets is claimed to be quicker absorption into the bloodstream at lower dosage levels.Fentanyl is not considered a first line opioid in palliative care.
Fentanyl (N-(1-(2-phenylethyl)-4-piperidinyl)-N-phenyl-propanamide) was approved by the USFDA in September 2006 for the management of breakthrough pain in patients with cancer who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain. One advantage of such tablets is claimed to be quicker absorption into the bloodstream at lower dosage levels.Fentanyl is not considered a first line opioid in palliative care.
